Vitamin B3 dose trial hopes to slow Alzheimer's brain decline
NCT ID NCT05617508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested different doses of nicotinamide riboside (a form of vitamin B3) in 80 people with early Alzheimer's disease. The goal was to find the dose that best boosts brain energy levels and changes brain metabolism with the fewest side effects. Participants took placebo or 1000-3000 mg of NR daily for 12 weeks, undergoing brain scans, spinal taps, and cognitive tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Haraldsplass Deaconess Hospital
Bergen, Vestland, 5009, Norway
-
Haukeland University Hospital
Bergen, Vestland, 5021, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of dementia cases reshape how we care for patients?
- Isolation in hospital may cloud the minds of older patients — a study investigates
- PET scans probe link between brain inflammation and Alzheimer's damage
- Can sound waves soothe Dementia's emotional turmoil?
- Can a Low-Dose immune calmer slow Alzheimer's decline?
- A stumble before memory slips? study tests if falls predict Alzheimer's